Luca Licata, MD

📢1/8 A subset of ER+/HER2- #breastcancer may benefit from #immunotherapy, but which tumors are these?🤔 Our latest study just out on @BrJCancer @SpringerNature sheds light on this highly relevant topic Read more:📌rdcu.be/dqys9 @BianchiniGP @mauricallari

New in @CCR_AACR: Neoadj. CT+IO improves pCR, EFS & OS in TNBC, but among those who relapse, most do so early (<24m)—especially in pts with residual disease (see below). Urgent need for trials in this high-risk group: ICI+ADC? ICI+VEGF? Bispecifics? 🔗 doi.org/10.1158/1078-0…

🔥 Camizestrant in SERENA-6 study demonstrated highly statistically significant and clinical meaningful ⬆️ PFS A landmark trial in oncology history: shifting treatment based on molecular (not clinical) progression by targeting its biological driver astrazeneca.com/media-centre/p…!

Just out on @JAMANetworkOpen our study on the fate of immunotherapy trials in breast cancer, led by @mariani_m97 Take a look at the terrific job and excellent tweetorial he did 👏 @BianchiniGP @SanRaffaeleMI @OncoAlert

Fantastic talk by @BianchiniGP at #ASCO2024 : "Does the Target Matter?" re ADCs. Must say, the insights were top-notch! But full disclosure: I might be a bit biased! 😅 #CancerResearch #ADCs

🔥ESMO Presidential Election: Voting opens today! I fully support Giuseppe Curigliano, who will dedicate his passion and determination to serving the ESMO community in this role. esmo.org/about-esmo/how…

How to navigate the practical challenges in immunotherapy for mTNBC - @LLicata88 @BianchiniG @curijoey @JavierCortesMD @lajos_pusztai oncodaily.com/68690.html #Cancer #CancerTreatment #Immunotherapy #MTNBC #OncoDaily #Oncology

Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer 💥It's an excellent review on optimizing the use of ICI in the management of metastatic TNBC👇 @OncoAlert cancertreatmentreviews.com/article/S0305-…

This narrative review summarizes the literature supporting the use of PARP inhibitors for breast cancer treatment, as well as potential future research directions. ja.ma/4ai7lDf

🙌Just out on @JAMAonc our review on PARPi for #breastcancer Many steps have been made in the last 20 yrs; a vast amount is left waiting to be explored. Great team effort led by @DFCI_BreastOnc and @IEOufficiale. Link 👉 jamanetwork.com/journals/jamao…

1/4 📢Calling all T-Dxd prescribers!💉 Out now in @FrontOncology our real-world study on the impact of antiemetic prophylaxis in patients treated with T-DXd highlighted the efficacy of the three-drug regimen (with NK1RA) doi.org/10.3389/fonc.2… @LLicata88 @BianchiniGP 🧵👇🏻👇🏻

Christmas dinner with the Bianchini’s crew 😁 @BianchiniGP